ImmunoPrecise Antibodies
🇨🇦Canada
- Country
- 🇨🇦Canada
- Ownership
- Public
- Established
- 1983-01-01
- Employees
- 101
- Market Cap
- $20.9M
- Introduction
ImmunoPrecise Antibodies Ltd. is a therapeutic antibody discovery company, which engages in the provision of human therapeutic antibody discovery and development services. The firm offers a selection of antibodies, enzymes, enzymes activity assays, arthritis animal products, proteins, deiminated proteins, and hybridoma licensing for research purposes. The co...
$20 Billion Market Breakthrough: IPA Pioneers High-Impact Antibody Development for Next
ImmunoPrecise Antibodies Ltd. announces breakthrough in TATX-112 program, targeting TrkB protein in aggressive cancers, positioning the company in a $20.7 billion market by 2028.
IPA Pioneers High-Impact Antibody Development for Next-Generation ADC Cancer Therapies
ImmunoPrecise Antibodies Ltd. announces breakthrough in TATX-112 program, targeting TrkB protein in aggressive cancers, positioning the company in a $20.7 billion market by 2028.
IPA Pioneers High-Impact Antibody Development for Next-Generation ADC Cancer
ImmunoPrecise Antibodies Ltd. announces breakthrough in TATX-112 program, targeting TrkB protein in aggressive cancers, positioning the company in a $20.7 billion market by 2028.
Boost For India's Generic Pharma Majors
India is a leading hub for biologics and biosimilars, with over the past decade seeing the largest number of approved biosimilars serving global patients. The government’s 2012 and 2016 guidelines have facilitated increased investment and established a regulatory framework for biosimilars, ensuring quality, safety, and efficacy. The loss of exclusivity for several patented biotech drugs in the U.S. has driven market growth, with accelerated biosimilar adoption in major markets. Leading domestic firms like Dr. Reddy’s are expanding their biologics facilities and product pipelines, with some products already commercialized globally.
© Copyright 2024. All Rights Reserved by MedPath